A phase I trial of RM-1929 in Japan
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2018
At a glance
- Drugs ASP 1929 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 16 Jan 2018 Status changed from planning to recruiting according to an Aspyrian Therapeutics media release.
- 21 Jul 2017 The MR states that the company is planning to start multiple phase I trials. However, the number of trials is not specified. I have created one CTP for now. Multiple profiles may have to be created later. I have assumed that trial will be conducted in patients.
- 21 Jul 2017 New trial record